C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas

Supportive Care in Cancer

Volumn 9, Issue 2, 2001, Pages 124-128

  Kallio, Raija ^a   Bloigu, Aini ^b   Surcel, Heljä Marja ^b   Syrjälä, Hannu ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Infections; Malignancy; Neoplastic fever

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SOLID TUMOR;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 0035087766     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200000181     Document Type: Article

References (42)

1. C-reactive protein and the acute phase response
2. Clinical studies of fever and infection in cancer
3. The erythrocyte sedimentation rate. Still a helpful test when used judiciously
4. Clinical utility of the erythrocyte sedimentation rate
5. The significance of fever in neoplastic disease
6. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer
7. Neoplastic fever responds to the treatment of an adequate dose of naproxen
8. Serum beta2 microglobulin and C-reactive protein in the monitoring of lymphomas: Findings in a multicenter study and experience in selected patients
9. The effect of naproxen on fever in patients with advanced gynecologic malignancies
10. Cytokines, the acute phase response and resting energy expenditure in cachectic patients with pancreatic cancer
11. Acute-phase protein response and survival duration of patients with pancreatic cancer
12. An elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer
13. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response
14. Acute-phase proteins and other systemic responses to inflammation
15. Investigation of infection in the neutropenic patients with fever
16. C-reactive protein levels in neutropenic patients with pyrexia
17. C-reactive protein during chemotherapy for acute leukemia with special reference to non-infective causes of fever
18. C-reactive protein: Its role in the diagnosis and follow-up of infectious diseases
19. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
20. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer
21. Continuous-monitoring blood culture screening system improves the detection of bacteremia in neutropenic patients
22. Fever of unexplained origin in patients with cancer
23. Evaluation of clinical and laboratory findings in leukaemic patients with blood culture positive for Staphylococcus epidermidis
24. C-reactive protein for rapid diagnosis of infection in leukaemia
25. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia
26. Why measure C-reactive protein?
27. Basic principles of ROC analysis
28. Serum C-reactive protein levels in disease
29. Acute phase response in bronchiectasis and bronchus carcinoma
30. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer
31. C-reactive protein fifty years on
32. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
33. Incidence and clinical significance of positive blood cultures in febrile episodes of patients with haematological malignancies
34. The objective measurement of remission and progression in metastatic breast cancer by the use of serum tumor markers. European group for serum tumor markers in breast cancer
35. Serial study of C-reactive protein during infection in leukaemia
36. On the possibility of differential diagnosis at elevated erythrocyte sedimentation rate by analysis of the concentration of blood plasma proteins - A model study
37. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer
38. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
39. The erythrocyte sedimentation rate. Guidelines for rational use
40. The effects of treatment with chemotherapy on the energy metabolism and inflammatory mediators in small-cell lung carcinoma
41. Acute-phase proteins or tumour markers: The role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases
42. The detection of infection in leukaemia by serial measurement of C-reactive protein